Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

US2025076311A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2025076311-A1
Application numberUS-202418929733-A
CountryUS
Kind codeA1
Filing dateOct 29, 2024
Priority dateDec 19, 2014
Publication dateMar 6, 2025
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.

First claim

Opening claim text (preview).

1 - 54 . (canceled) 55 . A method of treating an individual having an adipose tissue disorder comprising administering to the individual an effective amount of an antibody that binds to latent myostatin. 56 . The method of claim 55 , wherein the antibody blocks the release of mature myostatin from latent myostatin. 57 . The method of claim 55 , wherein the antibody does not bind to mature myostatin. 58 . The method of claim 55 , wherein the antibody binds to latent myostatin with higher affinity at neutral pH than at acidic pH. 59 . The method of claim 55 , wherein the antibody is a full-length IgG antibody.

Assignees

Inventors

Classifications

  • Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

  • Complementarity determining region [CDR] · CPC title

  • Constant or Fc region; Isotype · CPC title

  • Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

  • Cells for production · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2025076311A1 cover?
The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure als…
Who is the assignee on this patent?
Chugai Pharmaceutical Co Ltd
What technology area does this patent fall under?
Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Mar 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).